Eleonóra Klímová, Ján Rosocha, Štefan Raffač, Elena Tóthová
Bone marrow or peripheral blood hemopoietic stem cells transplantation has been proposed for the treatment of autoimmune diseases because of its immunosuppressive and immunomodulatory efects. Hemopoietic stem cell transplantation (HSCT) may destroy the aberrant immune system while recapitulation of lymphocyte ontogeny might either bring the disease to a lowel activity (autologous HSCT) or even cure it (allogenic HSCT). Always it is regard, that HSCT is an experimental type of MS treatment – with posssible use in progressive MS patients, who not respond to the conventional treatment and their control of the disease course is not satisfactory. The authors report long follow-up in four MS patients after HSCT.